OBJECTIVE: Biliary atresia is a neonatal obstructive cholangiopathy characterized by a destructive, obliterative process affecting both the intrahepatic and extrahepatic ducts of the biliary tree that uniquely presents in the first months of life. The consequence of progressive inflammatory and sclerotic reaction is the development of obstructive jaundice. To determine the proinflammatory cytokine profile in children with biliary atresia, we measured circulating levels of interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha and IL-8. METHODS: Twelve children, five males and seven females, with biliary atresia were studied. In addition, four patients with progressive familial intrahepatic cholestasis and three with Alagille syndrome were also included. Five patients with neonatal hepatitis were studied as controls of a liver disease without portal fibrosis. Serum concentration of total and conjugated bilirubin, gamma-glutamyl transferase and glutamic-pyruvic transaminase were measured by routine methods in all patients at time of sampling for the study. The degree of fibrosis in liver biopsies was scored using the histologic activity index. RESULTS: In our study IL-8 was detectable in 11 of 12 patients with biliary atresia with a median level of 262 pg/ml and a highly statistically significant difference (P < 0.0001) from controls. In patients with progressive familial intrahepatic cholestasis or with Alagille syndrome serum IL-8 levels were similarly elevated. In patients with neonatal hepatitis, IL-8 levels were marginally increased. Serum IL-8 levels were significantly correlated (Rs = 0.725, P < 0.0001) with the histologic activity index. CONCLUSIONS: Although further studies are needed to determine the role of IL-8 in portal inflammation, our results suggest that increased production of IL-8 may be a mechanism leading to the progressive portal inflammation and fibrosis in patients with chronic liver disease.
OBJECTIVE:Biliary atresia is a neonatal obstructive cholangiopathy characterized by a destructive, obliterative process affecting both the intrahepatic and extrahepatic ducts of the biliary tree that uniquely presents in the first months of life. The consequence of progressive inflammatory and sclerotic reaction is the development of obstructive jaundice. To determine the proinflammatory cytokine profile in children with biliary atresia, we measured circulating levels of interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha and IL-8. METHODS: Twelve children, five males and seven females, with biliary atresia were studied. In addition, four patients with progressive familial intrahepatic cholestasis and three with Alagille syndrome were also included. Five patients with neonatal hepatitis were studied as controls of a liver disease without portal fibrosis. Serum concentration of total and conjugated bilirubin, gamma-glutamyl transferase and glutamic-pyruvic transaminase were measured by routine methods in all patients at time of sampling for the study. The degree of fibrosis in liver biopsies was scored using the histologic activity index. RESULTS: In our study IL-8 was detectable in 11 of 12 patients with biliary atresia with a median level of 262 pg/ml and a highly statistically significant difference (P < 0.0001) from controls. In patients with progressive familial intrahepatic cholestasis or with Alagille syndrome serum IL-8 levels were similarly elevated. In patients with neonatal hepatitis, IL-8 levels were marginally increased. Serum IL-8 levels were significantly correlated (Rs = 0.725, P < 0.0001) with the histologic activity index. CONCLUSIONS: Although further studies are needed to determine the role of IL-8 in portal inflammation, our results suggest that increased production of IL-8 may be a mechanism leading to the progressive portal inflammation and fibrosis in patients with chronic liver disease.
Authors: Daniel Massó-Vallés; Toni Jauset; Erika Serrano; Nicole M Sodir; Kim Pedersen; Nesrine I Affara; Jonathan R Whitfield; Marie-Eve Beaulieu; Gerard I Evan; Laurence Elias; Joaquín Arribas; Laura Soucek Journal: Cancer Res Date: 2015-04-15 Impact factor: 12.701
Authors: Kathleen M Loomes; Cathie Spino; Nathan P Goodrich; Thomas N Hangartner; Amanda E Marker; James E Heubi; Binita M Kamath; Benjamin L Shneider; Philip Rosenthal; Paula M Hertel; Saul J Karpen; Jean P Molleston; Karen F Murray; Kathleen B Schwarz; Robert H Squires; Jeffrey Teckman; Yumirle P Turmelle; Estella M Alonso; Averell H Sherker; John C Magee; Ronald J Sokol Journal: Hepatology Date: 2018-12-27 Impact factor: 17.425
Authors: Kara L Calkins; Andrea DeBarber; Robert D Steiner; Martiniano J Flores; Tristan R Grogan; Susanne M Henning; Laurie Reyen; Robert S Venick Journal: JPEN J Parenter Enteral Nutr Date: 2017-12-18 Impact factor: 3.896
Authors: Anke Nijhuis; Renata Curciarello; Shameer Mehta; Roger Feakins; Cleo L Bishop; James O Lindsay; Andrew Silver Journal: Cell Tissue Res Date: 2017-02-11 Impact factor: 5.249
Authors: Oliver Glass; Ricardo Henao; Keyur Patel; Cynthia D Guy; Hans J Gruss; Wing-Kin Syn; Cynthia A Moylan; Robert Streilein; Russell Hall; Anna Mae Diehl; Manal F Abdelmalek Journal: Hepatol Commun Date: 2018-09-21
Authors: Maria Grazia Clemente; John T Patton; Robert A Anders; Robert H Yolken; Kathleen B Schwarz Journal: Biomed Res Int Date: 2015-07-13 Impact factor: 3.411